Phio Pharmaceuticals' Q3 Net Loss Widens to $4.2M on PH-762 Push

Phio Pharmaceuticals' Q3 2026 net loss widened to $4.2 million as R&D spending jumped 159%, with cash halving to $10.6 million ahead of a planned Phase 2b skin cancer study.